News

PharmiWeb11h
Riboscience Announces Successful Completion of Phase 1a Dose Escalation for RBS2418, a New Anti-Cancer Immunotherapy
PALO ALTO, CA / ACCESS Newswire / May 30, 2025 / Riboscience, LLC, today announced the presentation of data from the completed dose escalation Phase 1a of the Phase 1a/b clinical trial of the ENPP1 ...
S&P 500 Gains and Losses Today: FICO Shares Regain Ground After Recent Slump
The S&P 500 slipped 0.6% on Wednesday, May 28, ahead of semiconductor giant Nvidia's highly anticipated quarterly earnings ...
BMJ5d
Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial
Primary outcomes included relapse rates and time to relapse, with secondary outcomes including cognitive deficits, treatment response (the proportion of patients with≥1 point improvement in mRS within ...
archive6d
The History of Sexuality. Volume 1: An Introduction
An illustration of a magnifying glass. An illustration of a magnifying glass.